Acticor Biotech SAS announced the postponement of the publication of its annual results and universal registration document including its 2023 annual financial report, originally scheduled for April 30, 2024. The company will issue a release announcing the new date of approval and publication of the 2023 financial statements by the Board of Directors, as well as that of the annual financial report included in the 2023 Universal Registration Document.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.485 EUR | +12.53% | -25.38% | -83.28% |
Jul. 10 | Acticor: operations financed through to September | CF |
Jun. 04 | Acticor: hopes revived in stroke, share price rises | CF |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-83.28% | 8.29M | |
+20.95% | 127B | |
+23.00% | 117B | |
+26.72% | 27.77B | |
-19.75% | 20.44B | |
-14.90% | 16.62B | |
-16.56% | 15.92B | |
+11.19% | 14.74B | |
-46.65% | 14.94B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- ALACT Stock
- News Acticor Biotech SAS
- Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results